Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review

INTRODUCTION: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein ...

Descripción completa

Detalles Bibliográficos
Autores principales: Arru, Caterina, De Miglio, Maria Rosaria, Cossu, Antonio, Muroni, Maria Rosaria, Carru, Ciriaco, Zinellu, Angelo, Paliogiannis, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279985/
https://www.ncbi.nlm.nih.gov/pubmed/34105088
http://dx.doi.org/10.1007/s12325-021-01796-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279985/
https://www.ncbi.nlm.nih.gov/pubmed/34105088
http://dx.doi.org/10.1007/s12325-021-01796-6

Ejemplares similares